More than 60% of women with cancer who completed a 6-week digital cognitive behavior therapy intervention had their insomnia cured at 24 weeks.Phase 3 randomized trial data, presented at the European ...
TOKYO and STAMFORD, Conn., Jan. 15, 2019 /PRNewswire/ -- Eisai Co., Ltd. (CEO: Haruo Naito, "Eisai") and Purdue Pharma L.P. (President and CEO: Craig Landau, MD, "Purdue Pharma") today announced that ...
TOKYO--(BUSINESS WIRE)--SUSMED, Inc. (TOKYO:4263) announced that it obtained regulatory approval from the Ministry of Health, Labour and Welfare (the ”MHLW”) of SUSMED Med CBT-i® App for Insomnia (the ...
TOKYO, Jul 8, 2020 - (JCN Newswire) - - Eisai Co., Ltd. announced today that the new drug application for approval of its in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results